Birgitta Lauri

1.9k total citations
15 papers, 324 citations indexed

About

Birgitta Lauri is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Birgitta Lauri has authored 15 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Hematology and 5 papers in Molecular Biology. Recurrent topics in Birgitta Lauri's work include Chronic Lymphocytic Leukemia Research (7 papers), Multiple Myeloma Research and Treatments (6 papers) and Protein Degradation and Inhibitors (3 papers). Birgitta Lauri is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Multiple Myeloma Research and Treatments (6 papers) and Protein Degradation and Inhibitors (3 papers). Birgitta Lauri collaborates with scholars based in Sweden, United States and Belgium. Birgitta Lauri's co-authors include Jeanette Lundin, Lucia Ahlberg, Per Näsman, Torbjörn Karlsson, Gerd Lärfars, Anders Österborg, Anders Österborg, Stefan Norin, Claes Karlsson and Mattias Mattsson and has published in prestigious journals such as Blood, Leukemia and BMJ Open.

In The Last Decade

Birgitta Lauri

14 papers receiving 311 citations

Peers

Countries citing papers authored by Birgitta Lauri

Since Specialization

Citations

This map shows the geographic impact of Birgitta Lauri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgitta Lauri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgitta Lauri more than expected).

Fields of papers citing papers by Birgitta Lauri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgitta Lauri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgitta Lauri. The network helps show where Birgitta Lauri may publish in the future.

Co-authorship network of co-authors of Birgitta Lauri

This figure shows the co-authorship network connecting the top 25 collaborators of Birgitta Lauri. A scholar is included among the top collaborators of Birgitta Lauri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgitta Lauri. Birgitta Lauri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation‐wide real‐world report on consecutively identified patients 2023 ·European Journal Of Haematology ·(unknown), (unknown), Per Axelsson, Fredrik Ellin, Christian Kjellander, Karin Larsson, Birgitta Lauri, Catharina Lewerin, (unknown), (unknown), Hemming Johansson, Anders Österborg, Lotta Hansson	5
2	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study 2022 ·Cancer Reports ·Göran Wålinder, Anna Genell, Gunnar Juliusson, (unknown), (unknown), (unknown), Kristina Carlson, (unknown), Ljupco Veskovski, Birgitta Lauri, Johan Lund, Ingemar Turesson, Markus Hansson, Cecilie Blimark, Hareth Nahi	1
3	First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013 2018 ·Haematologica ·(unknown), (unknown), Hemming Johansson, Jenny Klintman, (unknown), (unknown), Eva Kimby, Stefan Norin, Per‐Ola Andersson, Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson	28
4	Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma 2018 ·Cancer Medicine ·Johan Lund, Astrid Gruber, Birgitta Lauri, Adil Doganay Duru, Cecilie Blimark, Agneta Swedin, Markus Hansson, Karin Forsberg, Lucia Ahlberg, (unknown), Anders Waage, Peter Gimsing, Annette Juul Vangsted, Ulf Christian Frølund, Erik Holmberg, Gösta Gahrton, Evren Alici, Mats Hardling, Ulf‐Henrik Mellqvist, Hareth Nahi	3
5	Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013 2017 ·Blood ·(unknown), (unknown), Hemming Johansson, Jenny Klintman, (unknown), (unknown), Eva Kimby, Stefan Norin, (unknown), Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson	1
6	Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program 2017 ·Blood ·(unknown), Per‐Ola Andersson, (unknown), Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Lotta Hansson, Anders Österborg	2
7	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial 2017 ·Cancer Chemotherapy and Pharmacology ·Ingrid Jakobsen Falk, Johan Lund, Henrik Gréen, Astrid Gruber, Evren Alici, Birgitta Lauri, Cecilie Blimark, Ulf‐Henrik Mellqvist, Agneta Swedin, Karin Forsberg, (unknown), Mats Hardling, Lucia Ahlberg, Kourosh Lotfi, Hareth Nahi	12
8	Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: CASTOR 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Andrew Spencer, Tomer M. Mark, Ivan Špıčka, Tamás Masszi, Birgitta Lauri, Mark‐David Levin, Alberto Bosi, Vânia Hungria, Michèle Cavo, Je‐Jung Lee, David Soong, Tineke Casneuf, Christopher Chiu, Xiang Qin, William Deraedt, Ming Qi, Kate Sasser, Jordan M. Schecter, Katja Weisel	2
9	European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide 2016 ·Blood ·Francesco Di Raimondo, Charalampia Kyriakou, Martin Schmidt‐Hieber, Marie‐Christiane Vekemans, Ángel Ramírez Páyer, (unknown), Birgitta Lauri, (unknown), Frederik Lersch, (unknown), Pamela Bacon, Torben Plesner	0
10	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group 2016 ·Haematologica ·(unknown), (unknown), Per Andersson, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Lotta Hansson, Anders Österborg	76
11	Prevalence of sexually transmitted infections in female clinic attendees in Honiara, Solomon Islands 2015 ·BMJ Open ·Michael Marks, (unknown), Robert Butcher, Birgitta Lauri, (unknown), (unknown), Oliver Sokana, (unknown), Adam Roth, Anthony W. Solomon, David Mabey	19
12	Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program 2015 ·Blood ·Lotta Hansson, (unknown), (unknown), (unknown), Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Anders Österborg	6
13	Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population. 2012 ·Blood ·Hareth Nahi, Johan Liwing, (unknown), Johan O. L. Andreasson, Cecilie Blimark, Kristina Carlson, (unknown), Max Flogegård, Karin Forsberg, Astrid Gruber, Peter Johansson, (unknown), Birgitta Lauri, Ulf‐Henrik Mellqvist, Per Näsman, Agneta Swedin, Magnus Svensson, Katarina Uttervall, J Aschan	1
14	Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study 2007 ·Leukemia ·(unknown), (unknown), Per Näsman, Lucia Ahlberg, Torbjörn Karlsson, Birgitta Lauri, Jeanette Lundin, Gerd Lärfars, Anders Österborg	159
15	Adjuvant intravenous iron therapy potentiates epoetin beta treatment in anemic, non iron-depleted patients with lymphoproliferative disorders : Results of the NIFE study 2006 ·Michael Hedenus, Gunnar Birgegård, Per Näsman, Lucia Ahlberg, Torbjörn Karlsson, Birgitta Lauri, Jeanette Lundin, Gerd Lärfars, Anders Österborg	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact